[Corrections] Correction to Lancet Oncol 2019; 20: 239–53

Leggi l'articolo originale


Scherpereel A, Mazieres J, Greillier L, et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol 2019; 20: 239–53—In figure 4B of this Article, the position of the plotted Kaplan-Meier curves on the y axis has been corrected, affecting the overall survival readings. This correction has been made to the online version as of March 1, 2019

Lascia un commento